FMP

FMP

Enter

LMNL - Liminal BioSciences ...

photo-url-https://images.financialmodelingprep.com/symbol/LMNL.png

Liminal BioSciences Inc.

LMNL

NASDAQ

Inactive Equity

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

8.5 USD

0.01 (0.118%)

LMNL Financial Statements

Year

2022

2021

2020

2019

Total Revenue

401k

643k

3.32M

4.9M

Cost of Revenue

0

0

2.03M

2.76M

Gross Profit

401k

643k

1.28M

2.14M

Operating Expenses

33.16M

50.27M

95.38M

120.4M

Research and Development

15.3M

18.35M

56.83M

75.11M

Selling, General & Administrative Expenses

17.87M

31.93M

38.55M

45.28M

Selling & Marketing Expenses

0

0

0

0

General & Administrative Expenses

0

0

0

0

Other Expenses

-212k

75k

79k

-92.37M

Operating Income

-32.98M

-49.56M

-94.27M

-210.63M

Total Other Income/Expenses Net

-525k

118k

-28.07M

-237k

Income Before Tax

-29.44M

-44.95M

-122.34M

-234.46M

Income Tax

-525k

118k

-201k

-237k

Net Income

-28.92M

-45.06M

-122.14M

-234.22M

Basic EPS

-9.32

-14.94

-49.97

-145.82

EPS Diluted

-9.32

-14.94

-49.97

-145.82

Basic Average Shares

3.1M

3.02M

2.44M

1.61M

Diluted Average Shares

3.1M

3.02M

2.44M

1.61M

EBITDA

-31.86M

-45.21M

-85.83M

-200.72M

Retained Earning Schedule

Year

2022

2021

2020

2019

Retained Earnings (Previous Year)

-1.07B

-1.09B

-967.05M

-755.69M

Net Income

-28.92M

-45.06M

-122.14M

-234.22M

Stock Repurchases

0

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-1.08B

-1.07B

-1.09B

-967.05M

Other Distributions

-8.13M

12.88M

-120M

-211.36M

PPE Schedule

Year

2022

2021

2020

2019

Gross PPE

5.49M

7.09M

27.35M

54.73M

Annual Depreciation

1.12M

4.34M

8.45M

9.91M

Capital Expenditure

-19k

-463k

-2.05M

-4.44M

Net PPE

4.39M

3.21M

20.95M

49.26M

Intangible and Goodwill Schedule

Year

2022

2021

2020

2019

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

0

0

0

0

Goodwill

0

0

0

0

All figures are in CAD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep